Innocan Pharma Corp. Stock
€0.11
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Innocan Pharma Corp.
sharewise wants to provide you with the best news and tools for Innocan Pharma Corp., so we directly link to the best financial data sources.
Financials
News
Innocan Pharma’s Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis
This is the second successful treatment in a donkey, demonstrating the potential of Innocan’s Liposomal CBD injection for human and veterinary use
Herzliya, Israel and Calgary, Alberta -
Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update
Herzliya, Israel and Calgary, Alberta – May 28, 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief
- Innocan’s first fully-granted patent in Mexico
- Covers Innocan’s proprietary cannabis-based pain relief topical
- Indication of Innocan’s growing intellectual
Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
Innovative Chronic Pain Treatment expand IP Protection in China’s US$163 Billion Pharmaceutical Market
Herzliya, Israel and Calgary, Alberta - April 07, 2025 - Innocan Pharma Corporation
Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million
Herzliya, Israel and Calgary, Alberta - March 31 2025 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
Innocan Pharma Granted First Patent in India for its Liposomal CBD Injection
Innovative Chronic Pain Treatment Receives IP Protection in India’s $55 Billion Pharmaceutical Market
Herzliya, Israel and Calgary, Alberta – February 18, 2025 – Innocan Pharma Corporation
Innocan Pharma’s Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone
Herzliya, Israel and Calgary, Alberta – January 29, 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
FDA’s Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025
Herzliya, Israel and Calgary, Alberta - January 9, 2025 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and